Spin-off Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

07-Jul-2021 - Scailyte, a single-cell biomarker discovery spin-off of ETH Zurich and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and ...

Using algorithms to track down cancer

08-Aug-2019 - Modern medicine is looking for markers that provide early warning of complex diseases. In its quest to discover these “biomarkers”, the ETH spinoff Scailyte has developed software capable of analysing millions of single cells very efficiently. The search for biomarkers is currently one of the ...

Scailyte raises CHF 2.75M in seed funding

Investments from Swisscom Ventures & Zürcher Kantonalbank

29-Jan-2019 - Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75Min seed fundingand gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank also joined the financing round, alongside the existing shareholders, thus reaffirming ...

ETH spin-off machine running at full speed

27 companies were founded in 2018, more than any year previously

08-Jan-2019 - In 2018, ETH Zurich achieved a new record high for the number of spin-offs founded: a total of 27 founding teams took the plunge into independence. While an average of 13 ETH spin-offs were founded per year from 2000 to 2010, the following decade has seen an average of 24 per year. For Detlef ...